Figure 1 | Scientific Reports

Figure 1

From: Hyperreflective foci in predicting the treatment outcomes of diabetic macular oedema after anti-vascular endothelial growth factor therapy

Figure 1

The average BCVA and CFT at the baseline and 3, 6, 12 months after anti-VEGF treatment for diabetic macular oedema. Both BCVA and CFT significantly improved compared with baseline at 3, 6, and 12 months after initial anti-VEGF treatment. BCVA best-corrected visual acuity, CFT central foveal thickness, VEGF vascular endothelial growth factor. *p < 0.001 (compared with baseline).

Back to article page